{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-020040","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.112456+00:00","generated_at":"2026-05-19T14:30:36.604057+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxart Phase 1 norovirus vaccine data: 141% (GI.1) and 94% (GII.4) antibody titer increases vs first-gen","bullets":["Second-gen constructs showed 141% increase in GI.1 and 94% increase in GII.4 NBAA titers vs first-gen at high dose, statistically significant.","All constructs safe and well-tolerated; no vaccine-related serious adverse events reported.","Vaxart plans Phase 2b as early as H2 2025, Phase 3 potentially in 2026, pending partnership/funding.","Company believes data supports potential for first-in-class or best-in-class oral norovirus vaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-020040","json":"https://secwatch.observer/filing/0001437749-25-020040.json","markdown":"https://secwatch.observer/filing/0001437749-25-020040.md","text":"https://secwatch.observer/filing/0001437749-25-020040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/0001437749-25-020040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/vxrt20250611_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T14:30:36.604057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}